{
    "clinical_study": {
        "@rank": "23512", 
        "arm_group": [
            {
                "arm_group_label": "OTX-DP (Dexamethasone Punctum Plug)", 
                "arm_group_type": "Active Comparator", 
                "description": "Resorbable hydrogel drug delivery vehicle containing dexamethasone"
            }, 
            {
                "arm_group_label": "PVPP (Placebo Punctum Plug)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Resorbable hydrogel drug delivery vehicle containing no drug"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone)\n      depot when placed in the canaliculus of the eyelid for  the treatment of post-surgical\n      inflammation and pain in subjects who have undergone cataract extraction with intra-ocular\n      lens implantation."
        }, 
        "brief_title": "Second Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Post Ocular Surgical Inflammation and Pain", 
        "condition_browse": {
            "mesh_term": "Inflammation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has a cataract and is expected to undergo clear corneal cataract surgery with\n             phacoemulsification and implantation of a posterior chamber lens\n\n          -  Has a potential post-operative pinhole corrected Snellen VA of at least 20/200 or\n             better in both eyes\n\n        Exclusion Criteria:\n\n          -  Any intraocular inflammation in the study eye present during the screening slit lamp\n             examination\n\n          -  Score greater than \"0\" on the Ocular Pain Assessment in the study eye at Screening\n\n          -  Any intraocular inflammation in the study eye present during the screening slit lamp\n             examination"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089113", 
            "org_study_id": "OTX-14-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "OTX-DP (Dexamethasone Punctum Plug)", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PVPP (Placebo Punctum Plug)", 
                "intervention_name": "Punctum Plug", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "info@fichte.com", 
                "last_name": "Michael Endl, MD", 
                "phone": "716-564-2020"
            }, 
            "facility": {
                "address": {
                    "city": "Amherst", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14228"
                }, 
                "name": "Fichte, Endl, and Elmer Eyecare"
            }, 
            "investigator": {
                "last_name": "Michael Endl, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "dmulani@ocutx.com", 
            "last_name": "Deepa Mulani", 
            "phone": "781-357-4023"
        }, 
        "overall_contact_backup": {
            "email": "scurwen@ocutx.com", 
            "last_name": "Stephen Curwen", 
            "phone": "781-357-4009"
        }, 
        "overall_official": {
            "affiliation": "Sponsor GmbH", 
            "last_name": "Deepa Mulani", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Absence of cells in anterior chamber of the study eye", 
            "safety_issue": "Yes", 
            "time_frame": "Day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089113"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cells in the anterior chamber in the study eye", 
                "safety_issue": "Yes", 
                "time_frame": "Days 2, 4, 8, 30"
            }, 
            {
                "measure": "Pain in the study eye", 
                "safety_issue": "Yes", 
                "time_frame": "Days 2, 4, 14, 30"
            }
        ], 
        "source": "Ocular Therapeutix, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ocular Therapeutix, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}